James Chen, MD
Hematology & Oncology · Columbus, OHNPI 1558520502
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $500 of the $650 with a category attached, or 77.0%. Every reported general payment came from a single manufacturer, Foundation Medicine, Inc.. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 3 payments — averaging $216.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$650
Across 26 payments — averaging $5262.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Epizyme, Inc.$71K
- Eisai Inc.$35K
- Karyopharm Therapeutics Inc.$31K
What the payments were for
- Consulting fees$50077%
- Speaking & faculty fees$11117%
- Food & beverage$396%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 3 | $650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$650 in reported general payments places this provider in the 30th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 11 | $112,593 |
| GleevecImatinib Mesylate | 12 | $93,005 |
| Abiraterone Acetate | 12 | $32,212 |
| Imatinib Mesylate | 24 | $10,486 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $392 |
| Oxycodone Hcl | 14 | $68 |
| Lisinopril | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Mark KnappColumbus$67K
- Kathleen KerriganColumbus$47K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.